FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure ... Forbes The FDA's Cardiovascular and Renal Drugs Advisory Committee voted unanimously (11-0) against approval of the biologics license application (BLA) for serelaxin (proposed trade name Reasanz). The novel drug from Novartis was intended to be used in ... Novartis Heart Failure Drug Fails to Win FDA Panel Backing FDA panel votes against Novartis drug for acute heart failure FDA Panel Rejects Novartis Drug for Heart Failure |
